Clinical Scorecard: When Does a Chimaera Cease to Be a Chimaera?
At a Glance
Category
Detail
Condition
Chimaerism following allogeneic haematopoietic cell transplantation (HCT)
Key Mechanisms
Replacement of recipient haemopoietic system by donor cells post-HCT; measurement of chimaeric status to monitor disease progression and graft-versus-host disease (GvHD)
Target Population
Recipients of allogeneic haematopoietic cell transplantation
Care Setting
Haematology and transplant clinical settings
Key Highlights
Radiation chimaeras result from successful allogeneic HCT where donor haemopoietic cells repopulate the recipient.
Measurement of chimaerism can predict relapse of leukaemia and risk of GvHD.
Techniques to detect chimaerism have evolved from PCR of STRs to fluorometric methods.
Guideline-Based Recommendations
Diagnosis
Use polymerase chain reaction (PCR) of polymorphic short tandem repeats (STRs) or fluorometric methods to detect donor and recipient haemopoietic cells post-HCT.
Management
Monitor chimaeric status to guide clinical decisions regarding relapse and GvHD risk.
Ensure donor-recipient matching to reduce secondary disease and improve survival.
Monitoring & Follow-up
Regular assessment of chimaerism levels to detect early signs of disease relapse or graft complications.
Risks
Non-matched donor cells increase risk of secondary disease and reduce survival.
Increase in recipient haemopoietic tissue post-HCT may indicate leukaemia relapse.
Graft versus Host Disease (GvHD) remains a significant complication.
